Guenter Stays Focused After Almirall's Annus Horribilis

Peter Guenter, brought in from Sanofi to fix the problems at Almirall, is staying focused on 2018 as he outlines his plan to rebuild the Spanish company. Almirall will continue reallocating resources and seeking bolt-on deals to establish a sustainable dermatology business as it rolls out Skilarence and tildrakizumab in Europe.

Ships wheel
Guenter steadies the ship at Almirall • Source: Shutterstock

Almirall SA's new CEO is seeking to reassure investors he steadied the ship in 2017 and has positioned it for future growth. Announcing a 16% drop in net sales to €639m last year, Peter Guenter emphasized ongoing cost savings, new control mechanisms and a focus on dermatology growth opportunities as his tools for getting Almirall on course for success. He promised a return to growth in revenues and earnings in 2018, but wouldn't offer any longer-term targets.

Among the challenges he has faced since assuming control at Almirall in October 2017 have been sorting out business irregularities...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.